Switzerland: Numab closes Series C financing for Sfr100m and adds to board

Numab Therapeutics, an oncology-focused biopharmaceutical company based near Zurich, has closed an oversubscribed Sfr100m (US$111m) Series C financing. Proceeds will support acceleration and expansion of the clinical development of Numab’s lead programme NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, into clinical trials. The…

You must be a HMI Subscriber to view this content.

Subscribe Now »